CO6680670A2 - Agonistas de ep4 prostaglandina útiles en la preparación de lal piel y la cicatrización de heridas - Google Patents

Agonistas de ep4 prostaglandina útiles en la preparación de lal piel y la cicatrización de heridas

Info

Publication number
CO6680670A2
CO6680670A2 CO13038986A CO13038986A CO6680670A2 CO 6680670 A2 CO6680670 A2 CO 6680670A2 CO 13038986 A CO13038986 A CO 13038986A CO 13038986 A CO13038986 A CO 13038986A CO 6680670 A2 CO6680670 A2 CO 6680670A2
Authority
CO
Colombia
Prior art keywords
wound healing
skin preparation
agonists useful
prostaglandin agonists
skin
Prior art date
Application number
CO13038986A
Other languages
English (en)
Inventor
Guan L Jiang
Robert M Bruk
Wha Bin Im
Federick C Beddingfield
Larry A Wheeler
Scott M Whitcup
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CO6680670A2 publication Critical patent/CO6680670A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)

Abstract

La descripción proporciona composiciones y métodos para tratar un defecto de la piel. Las composiciones comprenden una cantidad terapéuticamente eficaz de un compuesto útil para el tratamiento de defectos de la piel tales como heridas, cicatrices y arrugas.
CO13038986A 2010-07-30 2013-02-26 Agonistas de ep4 prostaglandina útiles en la preparación de lal piel y la cicatrización de heridas CO6680670A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36923210P 2010-07-30 2010-07-30
US41911510P 2010-12-02 2010-12-02

Publications (1)

Publication Number Publication Date
CO6680670A2 true CO6680670A2 (es) 2013-05-31

Family

ID=44543791

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13038986A CO6680670A2 (es) 2010-07-30 2013-02-26 Agonistas de ep4 prostaglandina útiles en la preparación de lal piel y la cicatrización de heridas

Country Status (17)

Country Link
US (1) US20120136011A1 (es)
EP (1) EP2598140B1 (es)
JP (1) JP2013536183A (es)
KR (1) KR20130130694A (es)
CN (1) CN103068382A (es)
AR (1) AR082428A1 (es)
AU (1) AU2011282549A1 (es)
BR (1) BR112013002319A2 (es)
CA (1) CA2806982A1 (es)
CL (1) CL2013000308A1 (es)
CO (1) CO6680670A2 (es)
MX (1) MX2013001227A (es)
NZ (1) NZ607306A (es)
RU (1) RU2013108394A (es)
SG (1) SG187653A1 (es)
TW (1) TW201210601A (es)
WO (1) WO2012016109A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697458B2 (en) 2009-04-22 2014-04-15 Shat-R-Shield, Inc. Silicone coated light-emitting diode
US8889123B2 (en) * 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) * 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8926963B2 (en) * 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US8697056B2 (en) * 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) * 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8900571B2 (en) * 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) * 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) * 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8741281B2 (en) * 2010-08-19 2014-06-03 Allergan, Inc. Compositions and soft tissue replacement methods
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
EP2919778A2 (en) * 2012-11-16 2015-09-23 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
WO2014078434A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Compounds and methods for skin repair
WO2015048553A1 (en) * 2013-09-27 2015-04-02 Allergan, Inc. Compounds and methods for skin repair
RU2625548C1 (ru) * 2015-04-29 2017-07-14 Жанна Юрьевна Юсова Способ коррекции возрастных изменений кожи лица
TWI593403B (zh) * 2016-12-01 2017-08-01 yi-ting Xu Remedial repair of facial damage
RU2663391C1 (ru) * 2018-01-30 2018-08-03 Игорь Николаевич Бондаренко Способ эстетической коррекции мягких тканей лица

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
EP1114816A4 (en) * 1998-09-14 2002-09-04 Ono Pharmaceutical Co SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES- $ g (V) AND MEDICINAL PRODUCTS CONTAINING THEM AS ACTIVE INGREDIENT
JP4618548B2 (ja) * 1999-11-24 2011-01-26 小野薬品工業株式会社 骨量低下疾患治療剤
TWI313608B (en) * 2001-07-23 2009-08-21 Ono Pharmaceutical Co Lower bone mass treating agent containing er4 agonist as active ingredient
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
TW200413000A (en) * 2002-10-10 2004-08-01 Ono Pharmaceutical Co Intrinsic repair factor producing accelerator
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
EP1608309B1 (en) * 2003-02-11 2012-07-11 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US6875787B2 (en) 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
WO2006016695A1 (ja) * 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
JP2006321737A (ja) * 2005-05-18 2006-11-30 Ono Pharmaceut Co Ltd Ｅｐ４アゴニストを含有する神経変性疾患の予防、治療および／または進展抑制剤
JP2007023028A (ja) * 2005-06-16 2007-02-01 Ono Pharmaceut Co Ltd 内耳疾患治療剤
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
KR20090089868A (ko) * 2006-12-15 2009-08-24 글락소 그룹 리미티드 Ｅｐ４ 수용체 작동제로서 벤즈아미드 유도체
CA2690273A1 (en) * 2006-12-18 2008-06-26 Allergan, Inc. Use of prostaglandin ep4 agonist for treating gastrointestinal disorders
AU2008246579A1 (en) * 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical

Also Published As

Publication number Publication date
CA2806982A1 (en) 2012-02-02
EP2598140A2 (en) 2013-06-05
WO2012016109A2 (en) 2012-02-02
WO2012016109A3 (en) 2012-03-22
JP2013536183A (ja) 2013-09-19
AU2011282549A1 (en) 2013-02-28
CN103068382A (zh) 2013-04-24
US20120136011A1 (en) 2012-05-31
AR082428A1 (es) 2012-12-05
KR20130130694A (ko) 2013-12-02
BR112013002319A2 (pt) 2016-05-24
CL2013000308A1 (es) 2013-04-12
SG187653A1 (en) 2013-03-28
RU2013108394A (ru) 2014-09-10
NZ607306A (en) 2015-03-27
EP2598140B1 (en) 2015-01-14
MX2013001227A (es) 2013-04-24
TW201210601A (en) 2012-03-16

Similar Documents

Publication Publication Date Title
CO6680670A2 (es) Agonistas de ep4 prostaglandina útiles en la preparación de lal piel y la cicatrización de heridas
EP3884931A3 (en) Multi-layer biomaterial for tissue regeneration and wound healing
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
DOP2010000282A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
CR20130356A (es) Dispositivos y metodos para tratamiento de heridas o de la piel
BR112014000775A2 (pt) curativo de ferimento e método de tratamento
CL2013001579A1 (es) Uso de una composicion farmaceutica que comprende un compuesto agonista ep4 para tratar marcas de la piel tales como heridas superficiales, cicatrices o arrugas.
RU2017127273A (ru) Короткие антимикробные липопептиды
BR112012030261A2 (pt) nova composição farmacêutica sinergística para a preparação de formulações tópicas para a pofilaxia e tratamento de feridas, feridas por queimaduras, exertos de pele, úlceras de pressão e úlceras do pé diabético
PE20180780A1 (es) Composicion y productos que comprenden celulas senescentes para su uso en la regeneracion de tejidos
CO7240418A2 (es) Apósito con una liberación prolongada de agentes activos
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
UY34096A (es) Soporte de colageno enrollado
EA201592073A1 (ru) Фармацевтические композиции, содержащие коллаген и гиалуронат натрия
PH12015502405A1 (en) Methods and compositions for wound healing
CL2015000254A1 (es) Vesículas que comprenden factor de crecimiento epidermico (egf); proceso de preparación; composición farmacéutica que las comprende; y uso para tratar heridas complejas .
EA201690854A1 (ru) Фармацевтические композиции с гидратирующим и смазывающим действием
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
EA201590049A1 (ru) Композиции и способы для лечения участков отсутствующей костной ткани и открытых переломов
EA201490209A1 (ru) Лечение избыточного менструального кровотечения, обусловленного фибромой матки
MX2015015379A (es) Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos.
BR112012029747A2 (pt) composição de tratamento da pele, método para fornecer um efeito antimicrobiano para a pele e utilização de uma composição
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы
UA54173U (ru) Способ асептизации раневых поверхностей у ж
RU2009123950A (ru) Способ лечения гнойных кожно-мышечных ран у животных

Legal Events

Date Code Title Description
FC Application refused